(R)-tert-butyl 2-(1-(4-(ethoxycarbonyl)phenyl)ethyl)hydrazinecarboxylate, 95%, 100mg

1-(5-Chloro-1H-indol-3-yl)-N,N-dimethylmethanamine, 95.0%, 1g

2-(2-Chlorophenyl)-5,7-dihydroxy-8-((3S,4R)-3-hydroxy-1-methylpiperidin-4-yl)-4H-chromen-4-one hydrochloride, 98%, 10mg

3-Bromopyridine, 99.0%, 500g

2,5-Dibromo-3-(dibromomethyl)pyridine, 98%, 5g

N-(2,3-DIMETHYL-4-NITROPHENYL)ACETAMIDE, 95.0%, 500mg

N-(Hydroxymethyl)benzamide>98.0%(GC)100g

Ethyl Cyclobutylideneacetate, 97.0%, 25g

5-Chlorothiophene-2-carboxamide, 97%, 250mg

2-Methoxy-5-(trifluoromethyl)benzamide, 5g

4-Carboxy-2,2,6,6-tetramethylpiperidine 1-Oxyl Free Radical, 97%, 100mg

2-Acetylpyridine>99.0%(GC)25mL

Microliter syringe GASTIGHT® series 1700 Point type 2, 100 µl, 1710 RN, 1 piece